Stay updated on Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial page.

Latest updates to the Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial page
- Check5 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2; no study content changes are evident on the page.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check27 days agoChange DetectedThe page now shows Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.1%

- Check41 days agoChange DetectedThe page's revision tag was updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check69 days agoChange DetectedAdded Revision: v3.4.2; removed the funding-lapse notice and Revision: v3.4.1.SummaryDifference0.5%

- Check76 days agoChange DetectedNotice about a lapse in government funding is now displayed on the page, with guidance about the NIH Clinical Center's status. The site revision has been updated from v3.4.0 to v3.4.1.SummaryDifference0.5%

- Check83 days agoChange DetectedThe page footer and glossary UI were updated: a glossary toggle is now shown, 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and 'Revision: v3.4.0' were added, while 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Relapsed Pediatric Solid Tumors Clinical Trial page.